IN2014MN01839A - - Google Patents

Info

Publication number
IN2014MN01839A
IN2014MN01839A IN1839MUN2014A IN2014MN01839A IN 2014MN01839 A IN2014MN01839 A IN 2014MN01839A IN 1839MUN2014 A IN1839MUN2014 A IN 1839MUN2014A IN 2014MN01839 A IN2014MN01839 A IN 2014MN01839A
Authority
IN
India
Prior art keywords
compounds
formula
relates
oxides
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjay Kumar
Rajiv Sharma
Vishal Ashok Mahajan
Sangameshwar Prabhakar Sawargave
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of IN2014MN01839A publication Critical patent/IN2014MN01839A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D307/08—Preparation of tetrahydrofuran
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1839MUN2014 2012-02-28 2013-02-27 IN2014MN01839A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603988P 2012-02-28 2012-02-28
US201261736622P 2012-12-13 2012-12-13
PCT/IB2013/051555 WO2013128378A1 (fr) 2012-02-28 2013-02-27 Dérivés d'acide phénylalcanoïque en tant qu'agonistes du rpg

Publications (1)

Publication Number Publication Date
IN2014MN01839A true IN2014MN01839A (fr) 2015-07-03

Family

ID=48225087

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1839MUN2014 IN2014MN01839A (fr) 2012-02-28 2013-02-27

Country Status (16)

Country Link
US (1) US20150072969A1 (fr)
EP (1) EP2820005A1 (fr)
JP (1) JP2015508809A (fr)
KR (1) KR20140138243A (fr)
CN (1) CN104144920A (fr)
AR (1) AR090191A1 (fr)
AU (1) AU2013227266A1 (fr)
CA (1) CA2866210A1 (fr)
IL (1) IL234254A (fr)
IN (1) IN2014MN01839A (fr)
MX (1) MX2014010272A (fr)
NZ (1) NZ631569A (fr)
RU (1) RU2014138894A (fr)
TW (1) TW201341356A (fr)
WO (1) WO2013128378A1 (fr)
ZA (1) ZA201407034B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755944B1 (fr) 2011-09-16 2017-06-14 Sanofi Dérivés de bi-aryle, leur préparation et leur application thérapeutique
WO2015028960A1 (fr) * 2013-08-28 2015-03-05 Piramal Enterprises Limited Dérivés hétérocycliques substitués en tant qu'agonistes de gpr et leurs utilisations
CN105722841A (zh) 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
WO2015084692A1 (fr) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
CA2935897C (fr) 2014-02-19 2018-07-03 Piramal Enterprises Limited Composes pouvant etre utilises a titre d'agonistes de gpr120
CA2955919A1 (fr) 2014-07-25 2016-01-28 Piramal Enterprises Limited Composes d'acide phenylalcanoique substitue utilisables en tant qu'agonistes de gpr120 et leurs utilisations
WO2016022742A1 (fr) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
WO2016019587A1 (fr) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Composés antidiabétiques bicycliques condensés [7, 6]
WO2016022448A1 (fr) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Composés bicycliques antidiabétiques
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
WO2016032120A1 (fr) * 2014-08-27 2016-03-03 씨제이헬스케어 주식회사 Nouveau dérivé d'amino-phényl-sulfonyl-acétate et son utilisation
KR101641023B1 (ko) 2014-08-27 2016-07-20 씨제이헬스케어 주식회사 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
EP3191463B1 (fr) 2014-09-11 2019-10-30 Piramal Enterprises Limited Composés hétérocycliques condensés à titre d'agonistes du gpr120
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (fr) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Inhibiteurs pd -1/pd-l1
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (fr) 2020-06-26 2021-12-30 Iyassu Sebhat Activateurs d'ampk
WO2024211164A2 (fr) * 2023-04-03 2024-10-10 Trustees Of Dartmouth College Mimétiques d'acides gras en tant que modulateurs de gpr40 et/ou gpr120

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3400392B2 (ja) * 1994-10-18 2003-04-28 ファイザー製薬株式会社 ５−リポキシゲナーゼ阻害剤及び新規医薬組成物
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
SK281577B6 (sk) * 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
CA2393027A1 (fr) * 1999-12-17 2001-06-21 Abbott Laboratories Inhibiteurs d'expression du gene de l'interleukine 5
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US7102008B2 (en) * 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
WO2005054213A1 (fr) * 2003-12-02 2005-06-16 Shionogi & Co., Ltd. Derive d'isoxazole presentant un effet agoniste sur le recepteur active par les proliferateurs des peroxysomes
EP1737809B1 (fr) * 2004-02-27 2013-09-18 Amgen, Inc Composes, compositions pharmaceutiques et procedes d'utilisation dans le traitement de troubles metaboliques
WO2005117909A2 (fr) 2004-04-23 2005-12-15 Exelixis, Inc. Modulateurs des proteines kinases et leurs methodes d'utilisation
RU2008122547A (ru) * 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
CA2651598A1 (fr) * 2006-05-18 2007-11-29 Wellstat Therapeutics Corporation Composes pour le traitement de troubles metaboliques
AU2007265966B2 (en) * 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
JP5591706B2 (ja) * 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
WO2009086277A1 (fr) * 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Benzènes tétrasubstitués
WO2009111056A1 (fr) 2008-03-06 2009-09-11 Amgen Inc. Dérivés d'acide carboxylique conformationnellement dépendants, utiles dans le traitement de troubles du métabolisme
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
EA022417B1 (ru) * 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
AU2009316019A1 (en) * 2008-11-14 2010-05-20 Bayer Intellectual Property Gmbh Heterocyclically substituted aryl compounds as HIF inhibitors
KR20120022801A (ko) 2009-04-22 2012-03-12 아스텔라스세이야쿠 가부시키가이샤 카르복실산 화합물
WO2010138901A1 (fr) * 2009-05-29 2010-12-02 Biogen Idec Ma Inc Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés
EP2453900A1 (fr) * 2009-07-17 2012-05-23 Shire LLC Nouvel acide amine de carbamate et promedicaments peptidiques d'opioïdes, et utilisations associees
DE102009046115A1 (de) * 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
IN2013CN01340A (fr) 2010-07-23 2015-08-07 Connexios Life Sciences Pvt Ltd
EP2651930B1 (fr) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Inhibiteurs biarylamide de production de leukotriènes

Also Published As

Publication number Publication date
EP2820005A1 (fr) 2015-01-07
AU2013227266A1 (en) 2014-10-02
TW201341356A (zh) 2013-10-16
KR20140138243A (ko) 2014-12-03
ZA201407034B (en) 2017-08-30
JP2015508809A (ja) 2015-03-23
WO2013128378A1 (fr) 2013-09-06
NZ631569A (en) 2016-10-28
US20150072969A1 (en) 2015-03-12
IL234254A (en) 2017-03-30
MX2014010272A (es) 2015-08-14
RU2014138894A (ru) 2016-04-20
AR090191A1 (es) 2014-10-29
CA2866210A1 (fr) 2013-09-06
CN104144920A (zh) 2014-11-12

Similar Documents

Publication Publication Date Title
JO3781B1 (ar) مشتقات الكينولون
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
PH12014502524B1 (en) Carboxylic acid compounds
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
WO2012116176A3 (fr) Urées asymétriques et utilisations médicales de celles-ci
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
IN2014MN00697A (fr)
WO2014170842A3 (fr) Utilisation de dérivés d'acides carboxyliques d'alkyle substitués comme agonistes du grp
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
MX2014006433A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2.
IN2013DN02555A (fr)
PH12013500671A1 (en) Novel gpr 119 agonists
IN2014KN01113A (fr)
IN2013MN00581A (fr)
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
MY168750A (en) Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists
MX2009013240A (es) Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
TN2010000318A1 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production
TH149194A (th) องค์ประกอบทางเภสัชกรรมของสารประกอบสไปโร-ออกซินโดล สำหรับการให้ยาเฉพาะที่และการใช้สารนั้นเป็นสารบำบัดรักษา